MIRA · Mira Pharmaceuticals, Inc.
$0.75
-0.02 (-2.60%)
At close · Aug 28
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We do not have sufficient cash and cash equivalents as of the date of filing this Quarterly Report on Form 10-Q to support our operations for at least the 12 months following the date the financial statements are issued. These conditions raise substantial doubt about our ability to continue as a going concern through 12 months after the date that the financial statements are issued.”View the 10-Q filed Aug 12, 2026
Market Cap
$31.52M
Shares
42.02M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Erez Aminov | CEO | $5,304,174 |
| Michelle Yanez | — | $116,712 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Erez Aminov | CEO | $3,140,263 |
| Former CFO | — | — |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Erez Aminov | CEO ^^ | $1,665,564 |
| Michelle Yanez | CFO ^^ | $541,624 |
| Adam Kaplin | former President & CSO ^^ | $199,600 |
| Jim McNulty | former CFO | $154,000 |
| Jude Uzonwanne | former CEO ^^ | $81,569 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Jude Uzonwanne | former CEO ^^ | $922,385 |
| Adam Kaplin | former President & CSO ^^ | $789,001 |
| Jim McNulty | former CFO | $366,869 |
| Erez Aminov | CEO ^^ | — |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Andriy Mushak | Fractional Chief Financial Officer | Appointed | 2026-06-08 |
| Edward MacPherson | director | Appointed | 2025-09-11 |
| Denil Nanji Shekhat, M.D. | director | Appointed | 2025-09-11 |
| Matthew Del Giudice, M.D. | director | Appointed | 2025-09-11 |
| Matthew Whalen | director | Appointed | 2025-09-11 |
| Erez Aminov | director | Appointed | 2025-09-11 |
| Alan Weichselbaum | Chief Financial Officer | Appointed | 2025-05-21 |
| Michelle Yanez | Chief Financial Officer, Treasurer and Secretary | Resigned | 2025-05-21 |
| Matthew Pratt Whalen | member of the Board | Appointed | 2024-11-21 |
| Michael Jerman | member of the board of directors | Resigned | 2024-11-21 |
| Ned MacPherson | member of the Board | Appointed | 2024-03-13 |
| Adam Kaplin | President and Chief Scientific Officer | Resigned | 2024-03-13 |
| Matthew P. Del Giudice | member of the Board | Appointed | 2024-03-13 |
| Denil N. Shekhat | member of the Board | Appointed | 2024-03-13 |
| Erez Aminov | Chairman of the Board | Appointed | 2024-03-13 |
| Chris Chapman | Executive Chairman | Resigned | 2024-03-13 |
| Hugh McColl | member of the Board | Resigned | 2024-03-13 |
| Brad Kroenig | member of the Board | Resigned | 2024-03-13 |
| Talhia Tuck | member of the Board | Resigned | 2024-03-13 |
| Christos Nicholoudis, Esq. | part-time General Counsel | Resigned | 2024-01-17 |
| Christos Nicholoudis, Esq. | Board of Directors | Resigned | 2024-01-17 |
| Brian Daly | Board of Directors | Resigned | 2023-12-01 |
| Michael Jerman | Chairman of the Audit Committee of the Board | Appointed | 2023-12-01 |
| Michael Jerman | Director | Appointed | 2023-11-20 |
| David Vorhoff | Board of Directors | Resigned | 2023-10-25 |